Manabu Miyata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manabu Miyata has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Akitaka Tsujikawa
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
42 shared publications Sotaro Ooto
Kyoto University Graduate School of Medicine
39 shared publicationsMasayuki Hata
29 shared publicationsAkitaka Tsujikawa
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, Japan
27 shared publications- Hiroshi Tamura
Kyoto University Graduate School of Medicine
27 shared publications Yuki Muraoka
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto City, Japan
27 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Elsevier in Ophthalmology Science
Reply to: Comment on “Nationwide multicenter survey of severe complications of strabismus surgery in Japan: Japanese Strabismus Surgery Study”
- 7 November 2026
- Published by Elsevier in Ophthalmology Science
Open AccessReply to: Comment on “Nationwide multicenter survey of severe complications of strabismus surgery in Japan: Japanese Strabismus Surgery Study”
- 22 October 2026
- Published by BMJ in British Journal of Ophthalmology
Reoperation risks of strabismus surgery across the lifespan: a nationwide cohort of 116 059 patients
Background/aims To determine the epidemiology of strabismus surgery and establish comprehensive benchmarks for reoperation risks across all age groups to guide future research and clinical management. Methods We conducted a nationwide, population-based, retrospective cohort study at the Onsite Research Centre, Kyoto, using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. We identified individuals undergoing strabismus surgery between 2011 and 2020. To identify the same individual across different claims, we used ‘ID0’, a unique identifier allowing record linkage. Results We identified 116 059 individuals (mean age, 27.4±25.1 years; 59 238 [51.0%] females). The age distribution was bimodal, peaking at 5–9 and 70–74 years. Exotropia was the most common subtype (59.4%), followed by esotropia (25.0%) and cyclovertical strabismus (15.6%). Cyclovertical strabismus was more prevalent in males (pConclusions Strabismus surgery exhibits a bimodal age distribution with a substantial burden in older adults. Cyclovertical strabismus carries the highest reoperation risk, particularly among older males. These comprehensive national estimates establish a baseline for future research and provide population-level prognostic data for clinical management.
- 22 October 2026
- Published by BMJ in British Journal of Ophthalmology
Reoperation risks of strabismus surgery across the lifespan: a nationwide cohort of 116 059 patients
Background/aims To determine the epidemiology of strabismus surgery and establish comprehensive benchmarks for reoperation risks across all age groups to guide future research and clinical management. Methods We conducted a nationwide, population-based, retrospective cohort study at the Onsite Research Centre, Kyoto, using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. We identified individuals undergoing strabismus surgery between 2011 and 2020. To identify the same individual across different claims, we used ‘ID0’, a unique identifier allowing record linkage. Results We identified 116 059 individuals (mean age, 27.4±25.1 years; 59 238 [51.0%] females). The age distribution was bimodal, peaking at 5–9 and 70–74 years. Exotropia was the most common subtype (59.4%), followed by esotropia (25.0%) and cyclovertical strabismus (15.6%). Cyclovertical strabismus was more prevalent in males (pConclusions Strabismus surgery exhibits a bimodal age distribution with a substantial burden in older adults. Cyclovertical strabismus carries the highest reoperation risk, particularly among older males. These comprehensive national estimates establish a baseline for future research and provide population-level prognostic data for clinical management.
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Surgical Workforce Contraction and Socioeconomic Burden in a Super-Aged Society: A Nationwide Simulation of Strabismus Surgery in Japan
Background: Global aging threatens specialised surgical capacity. We forecast the macroeconomic burden of this supply-demand mismatch and monetised the resulting socioeconomic deficit in a super-aged society, using strabismus surgery as a predictive model.Methods: We integrated patient-level strabismus surgery data from the National Database of Health Insurance Claims (>95% population coverage; 2011–2020) with national workforce projections (2025–2045). We projected supply-demand imbalances using an unadjusted headcount and a full-time equivalent (FTE)-adjusted model. We constructed a deterministic decision-analytic model to monetise lost quality-adjusted life years (QALYs) caused by surgical delays using a standard willingness-to-pay threshold, incorporating a one-way sensitivity analysis for key parameters including surgical wait times.Findings: By 2045, surgical demand decreases by 16.3%. However, the active surgical workforce contracts by 31.1% (unadjusted) and 31.2% (FTE-adjusted) primarily due to the retirement of current high-volume cohorts and structural limits on younger physicians’ FTE capacity. This workforce attrition outpaces the demand decline, increasing the individual surgeon workload by 21.6% to 21.7%. This capacity shortfall generates 31,740 patient-years of surgical delay between 2026 and 2045, resulting in an estimated loss of 3,491 QALYs and an avoidable socioeconomic burden of $107.3 million ($53.6 million–$160.9 million), with surgical wait time driving the greatest variance.Interpretation: Surgical workforce attrition outpaces demographic demand decline, creating profound societal deficits and forcing geographical care centralisation. Sustaining equitable access requires integrating artificial intelligence for operational efficiency and increasing reimbursement rates to prevent surgeon migration to lucrative cash-pay sectors.Funding: Japan Society for the Promotion of Science (No. 25K12870).
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSurgical Workforce Contraction and Socioeconomic Burden in a Super-Aged Society: A Nationwide Simulation of Strabismus Surgery in Japan
Background: Global aging threatens specialised surgical capacity. We forecast the macroeconomic burden of this supply-demand mismatch and monetised the resulting socioeconomic deficit in a super-aged society, using strabismus surgery as a predictive model.Methods: We integrated patient-level strabismus surgery data from the National Database of Health Insurance Claims (>95% population coverage; 2011–2020) with national workforce projections (2025–2045). We projected supply-demand imbalances using an unadjusted headcount and a full-time equivalent (FTE)-adjusted model. We constructed a deterministic decision-analytic model to monetise lost quality-adjusted life years (QALYs) caused by surgical delays using a standard willingness-to-pay threshold, incorporating a one-way sensitivity analysis for key parameters including surgical wait times.Findings: By 2045, surgical demand decreases by 16.3%. However, the active surgical workforce contracts by 31.1% (unadjusted) and 31.2% (FTE-adjusted) primarily due to the retirement of current high-volume cohorts and structural limits on younger physicians’ FTE capacity. This workforce attrition outpaces the demand decline, increasing the individual surgeon workload by 21.6% to 21.7%. This capacity shortfall generates 31,740 patient-years of surgical delay between 2026 and 2045, resulting in an estimated loss of 3,491 QALYs and an avoidable socioeconomic burden of $107.3 million ($53.6 million–$160.9 million), with surgical wait time driving the greatest variance.Interpretation: Surgical workforce attrition outpaces demographic demand decline, creating profound societal deficits and forcing geographical care centralisation. Sustaining equitable access requires integrating artificial intelligence for operational efficiency and increasing reimbursement rates to prevent surgeon migration to lucrative cash-pay sectors.Funding: Japan Society for the Promotion of Science (No. 25K12870).
- Open Access
- 5 October 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 293, 20-33
Three-Dimensional Architecture of Outer Retinal Tubulation in Bietti Crystalline Dystrophy
- 5 October 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 293, 20-33
Open AccessThree-Dimensional Architecture of Outer Retinal Tubulation in Bietti Crystalline Dystrophy
- 21 September 2026
- Published by Wolters Kluwer Health in Retina
ACUTE NEUROSENSORY RETINAL THINNING AND SHORT-TERM VISUAL OUTCOMES IN MASSIVE SUBMACULAR HEMORRHAGE: A LONGITUDINAL ANALYSIS FROM PRE-ONSET TO POST-DISPLACEMENT WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR
Purpose: To investigate longitudinal visual and structural changes from pre-onset to 1 month postoperatively in eyes with massive submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD) treated with subretinal tissue plasminogen activator (tPA) injection and to identify prognostic factors for visual outcomes. Methods: This retrospective observational study reviewed the medical records of consecutive eyes with massive SMH secondary to nAMD treated with pars plana vitrectomy with subretinal tPA injection and pneumatic displacement. We assessed best-corrected visual acuity (BCVA) and foveal sensory retinal thickness (FSRT) at pre-onset, preoperative, and 1-month postoperative time points. Results: Among 74 consecutive eyes treated with subretinal tPA injection for massive SMH, we analyzed 20 eyes with available pre-onset data. FSRT decreased significantly from 193.5 ± 101.4 μm at pre-onset to 107.0 ± 59.0 μm at 1 month postoperatively ( P < 0.001). BCVA change negatively correlated with FSRT change (r = −0.56, P = 0.01). Univariable analysis showed that pre-onset BCVA significantly correlated with 1-month BCVA (r = 0.45, P = 0.049). At pre-onset, persistent fluid and pigment epithelial detachment were present in 65% and 15%, respectively. Conclusions: Massive SMH causes acute and profound neurosensory retinal thinning, and pre-onset neuronal integrity may be a key determinant of visual outcomes. Because surgery cannot reverse this immediate damage, preventing hemorrhage by maintaining a strictly fluid-free macula may be an important proactive strategy.
- 21 September 2026
- Published by Wolters Kluwer Health in Retina
ACUTE NEUROSENSORY RETINAL THINNING AND SHORT-TERM VISUAL OUTCOMES IN MASSIVE SUBMACULAR HEMORRHAGE: A LONGITUDINAL ANALYSIS FROM PRE-ONSET TO POST-DISPLACEMENT WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR
Purpose: To investigate longitudinal visual and structural changes from pre-onset to 1 month postoperatively in eyes with massive submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD) treated with subretinal tissue plasminogen activator (tPA) injection and to identify prognostic factors for visual outcomes. Methods: This retrospective observational study reviewed the medical records of consecutive eyes with massive SMH secondary to nAMD treated with pars plana vitrectomy with subretinal tPA injection and pneumatic displacement. We assessed best-corrected visual acuity (BCVA) and foveal sensory retinal thickness (FSRT) at pre-onset, preoperative, and 1-month postoperative time points. Results: Among 74 consecutive eyes treated with subretinal tPA injection for massive SMH, we analyzed 20 eyes with available pre-onset data. FSRT decreased significantly from 193.5 ± 101.4 μm at pre-onset to 107.0 ± 59.0 μm at 1 month postoperatively ( P < 0.001). BCVA change negatively correlated with FSRT change (r = −0.56, P = 0.01). Univariable analysis showed that pre-onset BCVA significantly correlated with 1-month BCVA (r = 0.45, P = 0.049). At pre-onset, persistent fluid and pigment epithelial detachment were present in 65% and 15%, respectively. Conclusions: Massive SMH causes acute and profound neurosensory retinal thinning, and pre-onset neuronal integrity may be a key determinant of visual outcomes. Because surgery cannot reverse this immediate damage, preventing hemorrhage by maintaining a strictly fluid-free macula may be an important proactive strategy.
- Open Access
- 11 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0349947
Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration
This retrospective study compared the short-term efficacy of a two-dose intravitreal aflibercept (IVA) 8-mg loading regimen (2024–2025) with a conventional three-dose IVA 2-mg regimen (2013–2014) for treatment-naïve neovascular age-related macular degeneration (nAMD). Using 1:1 propensity score matching for age, sex, nAMD subtype, and baseline visual acuity, we evaluated 31 eyes per group. The primary endpoint was the proportion of eyes achieving a fluid-free center subfield one month after completing the respective loading phase (at 2 and 3 months from baseline, respectively). The fluid-free proportion was numerically higher in the 8-mg group (90.3%; 95% confidence interval [CI], 74.2–98.0%) than in the 2-mg group (80.6%; 95% CI, 62.5–92.5%); however, the difference was not statistically significant ( P = 0.28). Both regimens yielded significant reductions in central retinal thickness, central choroidal thickness, and pigment epithelial detachment height, with no significant between-group differences. Within the 8-mg group, baseline intraretinal fluid strongly correlated with one-month visual acuity (r = 0.61, P < 0.001). These exploratory findings suggest that a reduced two-dose aflibercept 8-mg loading regimen provided short-term anatomical outcomes that did not differ significantly from the standard three-dose 2-mg regimen. This shortened loading phase potentially reduces the initial treatment burden. Further prospective studies should validate these preliminary outcomes.
- 11 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0349947
Open AccessTwo-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration
This retrospective study compared the short-term efficacy of a two-dose intravitreal aflibercept (IVA) 8-mg loading regimen (2024–2025) with a conventional three-dose IVA 2-mg regimen (2013–2014) for treatment-naïve neovascular age-related macular degeneration (nAMD). Using 1:1 propensity score matching for age, sex, nAMD subtype, and baseline visual acuity, we evaluated 31 eyes per group. The primary endpoint was the proportion of eyes achieving a fluid-free center subfield one month after completing the respective loading phase (at 2 and 3 months from baseline, respectively). The fluid-free proportion was numerically higher in the 8-mg group (90.3%; 95% confidence interval [CI], 74.2–98.0%) than in the 2-mg group (80.6%; 95% CI, 62.5–92.5%); however, the difference was not statistically significant ( P = 0.28). Both regimens yielded significant reductions in central retinal thickness, central choroidal thickness, and pigment epithelial detachment height, with no significant between-group differences. Within the 8-mg group, baseline intraretinal fluid strongly correlated with one-month visual acuity (r = 0.61, P < 0.001). These exploratory findings suggest that a reduced two-dose aflibercept 8-mg loading regimen provided short-term anatomical outcomes that did not differ significantly from the standard three-dose 2-mg regimen. This shortened loading phase potentially reduces the initial treatment burden. Further prospective studies should validate these preliminary outcomes.
- 25 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Teprotumumab effects on thyroid eye disease in a Japanese MRI study: comparison with intravenous glucocorticoid therapy
Context: Teprotumumab (TEP) is an emerging treatment for thyroid eye disease (TED), but real-world evidence outside the United States remains limited, and detailed changes in orbital components have not been fully clarified. Objective: To evaluate the effectiveness of TEP based on clinical manifestations and magnetic resonance imaging (MRI) findings and compare it with that of intravenous glucocorticoid (IVGC) therapy. Methods: The TEP cohort included all 18 patients who started TEP therapy at Kyoto University Hospital by 31 July 2025. A historical IVGC cohort included 20 patients selected to improve comparability with the TEP cohort. Results: During 24 weeks of TEP therapy, proptosis measured using a Hertel exophthalmometer improved from 22 (20-22) to 19 (16-21) mm (P = .025), and clinical activity score decreased from 4 (3-5) to 1 (0-1) point (P < .001). Among 15 patients with diplopia, a reduction of at least 1 point in Gorman score was observed in 9 patients (60.0%). Thyroid-stimulating antibody titers decreased from 1180% (349-4710) to 282% (132-504) (P = .013). Magnetic resonance imaging–based comparisons with the IVGC cohort showed that TEP reduced both extraocular muscle and orbital fat areas, whereas IVGC reduced extraocular muscle area but conversely increased orbital fat area. Inflamed extraocular muscles identified on MRI were enlarged at baseline and showed marked shrinkage after both therapies. Conclusion: Teprotumumab showed robust effectiveness in Japanese real-world patients with TED. Magnetic resonance imaging–based analyses revealed distinct effects of TEP and IVGC on orbital fat and identified inflamed extraocular muscles as treatment-responsive components.
- 25 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Teprotumumab effects on thyroid eye disease in a Japanese MRI study: comparison with intravenous glucocorticoid therapy
Context: Teprotumumab (TEP) is an emerging treatment for thyroid eye disease (TED), but real-world evidence outside the United States remains limited, and detailed changes in orbital components have not been fully clarified. Objective: To evaluate the effectiveness of TEP based on clinical manifestations and magnetic resonance imaging (MRI) findings and compare it with that of intravenous glucocorticoid (IVGC) therapy. Methods: The TEP cohort included all 18 patients who started TEP therapy at Kyoto University Hospital by 31 July 2025. A historical IVGC cohort included 20 patients selected to improve comparability with the TEP cohort. Results: During 24 weeks of TEP therapy, proptosis measured using a Hertel exophthalmometer improved from 22 (20-22) to 19 (16-21) mm (P = .025), and clinical activity score decreased from 4 (3-5) to 1 (0-1) point (P < .001). Among 15 patients with diplopia, a reduction of at least 1 point in Gorman score was observed in 9 patients (60.0%). Thyroid-stimulating antibody titers decreased from 1180% (349-4710) to 282% (132-504) (P = .013). Magnetic resonance imaging–based comparisons with the IVGC cohort showed that TEP reduced both extraocular muscle and orbital fat areas, whereas IVGC reduced extraocular muscle area but conversely increased orbital fat area. Inflamed extraocular muscles identified on MRI were enlarged at baseline and showed marked shrinkage after both therapies. Conclusion: Teprotumumab showed robust effectiveness in Japanese real-world patients with TED. Magnetic resonance imaging–based analyses revealed distinct effects of TEP and IVGC on orbital fat and identified inflamed extraocular muscles as treatment-responsive components.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-7
Ophthalmological Abnormalities in Cases with Intracranial Aneurysms: A Retrospective Referral-Based Study
Background: Intracranial aneurysms affect 2– 3% of the population. Ophthalmological symptoms, such as ophthalmoplegia and visual field defects, can be symptoms of unruptured intracranial aneurysms. In this study, we reported the frequency of ophthalmological abnormalities and the relationship between these abnormalities and treatment and life prognosis. Methods: One hundred forty-two patients who were referred from the Kyoto University Hospital Neurosurgery Department to the Ophthalmology Department between January 2011 and October 2022 were enrolled in this study. Age, sex, aneurysm location, visual field defects, ophthalmoplegia, presence of subarachnoid hemorrhage, treatment, and death during follow-up were retrospectively investigated. Results: Of the 142 patients, internal carotid artery aneurysms were the most frequent (93 cases), followed by internal carotid-posterior communicating artery (IC-PC) aneurysms (20 cases). Cranial nerve III palsy was observed in 50% of cases with IC-PC aneurysms, and this frequency was higher compared to cases with other aneurysms (p=0.0095). Post-chiasmal visual field defects were present not only in patients with anterior circulation aneurysms (anterior communicating artery, 25%; internal carotid artery, 19%; and middle cerebral artery, 33%), but also in patients with posterior circulation aneurysms (basilar artery, 21%). Conclusions: Cranial aneurysm not only causes III palsies but also causes visual field defects. Our findings support careful ophthalmologic assessment, including visual field testing when clinically feasible, especially when aneurysms are large or near the visual pathway, regardless of the anatomical position of the originating artery.
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-7
Open AccessOphthalmological Abnormalities in Cases with Intracranial Aneurysms: A Retrospective Referral-Based Study
Background: Intracranial aneurysms affect 2– 3% of the population. Ophthalmological symptoms, such as ophthalmoplegia and visual field defects, can be symptoms of unruptured intracranial aneurysms. In this study, we reported the frequency of ophthalmological abnormalities and the relationship between these abnormalities and treatment and life prognosis. Methods: One hundred forty-two patients who were referred from the Kyoto University Hospital Neurosurgery Department to the Ophthalmology Department between January 2011 and October 2022 were enrolled in this study. Age, sex, aneurysm location, visual field defects, ophthalmoplegia, presence of subarachnoid hemorrhage, treatment, and death during follow-up were retrospectively investigated. Results: Of the 142 patients, internal carotid artery aneurysms were the most frequent (93 cases), followed by internal carotid-posterior communicating artery (IC-PC) aneurysms (20 cases). Cranial nerve III palsy was observed in 50% of cases with IC-PC aneurysms, and this frequency was higher compared to cases with other aneurysms (p=0.0095). Post-chiasmal visual field defects were present not only in patients with anterior circulation aneurysms (anterior communicating artery, 25%; internal carotid artery, 19%; and middle cerebral artery, 33%), but also in patients with posterior circulation aneurysms (basilar artery, 21%). Conclusions: Cranial aneurysm not only causes III palsies but also causes visual field defects. Our findings support careful ophthalmologic assessment, including visual field testing when clinically feasible, especially when aneurysms are large or near the visual pathway, regardless of the anatomical position of the originating artery.
- Open Access
- 19 May 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (7) , 101243
Nationwide Multicenter Survey of Severe Complications of Strabismus Surgery in Japan: Japanese Strabismus Surgery Study
- 19 May 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (7) , 101243
Open AccessNationwide Multicenter Survey of Severe Complications of Strabismus Surgery in Japan: Japanese Strabismus Surgery Study
- Open Access
- 22 April 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (4) , e0001382
Uptrend in esotropia incidence in the era of excessive smartphone use: A nationwide population-based cohort study in Japan, 2014–2019
Acute acquired comitant esotropia (AACE) has recently garnered attention, as numerous case-series studies have reported its occurrence following excessive smartphone use. However, no large-scale epidemiological evidence of an increase in esotropia has been provided. This study aimed to investigate the change in the annual incidence of esotropia in Japan between 2014 and 2019—a period marked by a rapid increase in smartphone users. This nationwide population-based cohort study used the National Database of Health Insurance Claims and Specific Health Checkups of Japan, which covers almost the entire Japanese population. We counted the number of newly diagnosed esotropia cases and esotropia-related strabismus surgeries for each year from 2014 to 2019. Annual incidence rates were calculated by dividing these numbers by the corresponding year’s population. We also investigated the correlation between the annual incidence rate and smartphone household penetration, based on data from the Japanese Ministry of Internal Affairs and Communications. The annual incidence of esotropia gradually increased from 32.26 (95% confidence interval [CI], 31.95–32.57) to 36.61 (95% CI, 36.28–36.95) per 100,000 person-years between 2014 and 2019. The mean annual increase rate was 2.49 ± 1.62%. The number of esotropia-related strabismus surgeries also increased from 3,061 to 3,743 during the same period. The annual incidence of esotropia correlated significantly with smartphone household penetration ( P = 0.005, r = 0.943). In conclusion, this ecological study provides the first population-based evidence of a significant uptrend in the annual incidence of esotropia and related strabismus surgeries in Japan between 2014 and 2019. The rapid increase in digital device use warrants caution and may be associated with this increase, suggesting a need for clinical guidelines on screen time.
- 22 April 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (4) , e0001382
Open AccessUptrend in esotropia incidence in the era of excessive smartphone use: A nationwide population-based cohort study in Japan, 2014–2019
Acute acquired comitant esotropia (AACE) has recently garnered attention, as numerous case-series studies have reported its occurrence following excessive smartphone use. However, no large-scale epidemiological evidence of an increase in esotropia has been provided. This study aimed to investigate the change in the annual incidence of esotropia in Japan between 2014 and 2019—a period marked by a rapid increase in smartphone users. This nationwide population-based cohort study used the National Database of Health Insurance Claims and Specific Health Checkups of Japan, which covers almost the entire Japanese population. We counted the number of newly diagnosed esotropia cases and esotropia-related strabismus surgeries for each year from 2014 to 2019. Annual incidence rates were calculated by dividing these numbers by the corresponding year’s population. We also investigated the correlation between the annual incidence rate and smartphone household penetration, based on data from the Japanese Ministry of Internal Affairs and Communications. The annual incidence of esotropia gradually increased from 32.26 (95% confidence interval [CI], 31.95–32.57) to 36.61 (95% CI, 36.28–36.95) per 100,000 person-years between 2014 and 2019. The mean annual increase rate was 2.49 ± 1.62%. The number of esotropia-related strabismus surgeries also increased from 3,061 to 3,743 during the same period. The annual incidence of esotropia correlated significantly with smartphone household penetration ( P = 0.005, r = 0.943). In conclusion, this ecological study provides the first population-based evidence of a significant uptrend in the annual incidence of esotropia and related strabismus surgeries in Japan between 2014 and 2019. The rapid increase in digital device use warrants caution and may be associated with this increase, suggesting a need for clinical guidelines on screen time.